文献速递瓣膜外科

二尖瓣经导管缘对缘修复术后再干预的发生率、特征与结局

Incidence, characteristics, and outcomes of reintervention after mitral transcatheter edge-to-edge repair.
PubMed 文献 · J Thorac Cardiovasc Surg · 2022-04-13

基于美国Medicare数据,2013年7月至2017年11月共11,396例初次二尖瓣经导管缘对缘修复(TEER)患者中,548例(4.8%)在中位4.5个月后接受再干预。再干预类型为重复TEER 294例(53.7%)与二尖瓣手术(MVS)254例(46.3%)。再干预后30天死亡率为8.6%,再干预是长期死亡的独立危险因素(HR 3.26)。

要点

  • 初次TEER后再干预发生率为4.8%(548/11,396),中位时间4.5个月。
  • 再干预后30天死亡率为8.6%,30天再入院率为20.9%,30天复合并发症率为48.2%。
  • 再干预是长期死亡的独立危险因素(HR 3.26,95%CI 2.53-4.20)。

核心结论

  • 初次TEER后再干预是一种高风险操作,带来显著的死亡负担,凸显确保初次TEER手术成功以避免再干预并发症的重要性。

研究设计与样本

  • 基于Medicare受益人数据的全国代表性研究,回顾2013年7月至2017年11月共11,396例接受初次TEER的患者,前瞻性追踪并识别重复TEER或MVS。

主要发现

  • 11,396例初次TEER患者中548例(4.8%)需要再干预,中位时间间隔4.5个月。
  • 再干预后总体30天死亡率为8.6%,30天再入院率为20.9%,30天复合并发症率为48.2%。
  • 再干预类型中重复TEER 294例(53.7%),MVS 254例(46.3%)。
  • MVS组较重复TEER组更年轻且女性更多,但合并症负担相似。
  • 校正后,MVS组与重复TEER组30天死亡率(AOR 1.26,95%CI 0.65-2.45)和30天再入院率(AOR 1.14,95%CI 0.72-1.81)无差异;MVS组30天并发症率高于重复TEER组(AOR 4.76,95%CI 3.17-7.14)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The use of transcatheter edge-to-edge repair (TEER) is growing substantially, and reintervention after TEER by way of repeat TEER or mitral valve surgery (MVS) is increasing as a result. In this nationally representative study we examined the incidence, characteristics, and outcomes of reintervention after index TEER. METHODS: Between July 2013 and November 2017, we reviewed 11,396 patients who underwent index TEER using Medicare beneficiary data. These patients were prospectively tracked and identified as having repeat TEER or MVS. Primary outcomes included 30-day mortality, 30-day readmission, 30-day composite morbidity, and cumulative survival. RESULTS: Among 11,396 patients who underwent TEER, 548 patients (4.8%) required reintervention after a median time interval of 4.5 months. Overall 30-day mortality was 8.6%, 30-day readmission was 20.9%, and 30-day composite morbidity was 48.2%. According to reintervention type, 294 (53.7%) patients underwent repeat TEER, and 254 (46.3%) underwent MVS. Patients who underwent MVS were more likely to be younger and female, but had a similar comorbidity burden compared with the repeat TEER cohort. After adjustment, there were no differences in 30-day mortality (adjusted odds ratio [AOR], 1.26 [95% CI, 0.65-2.45]) or 30-day readmission (AOR, 1.14 [95% CI, 0.72-1.81]). MVS was associated with higher 30-day morbidity (AOR, 4.76 [95% CI, 3.17-7.14]) compared with repeat TEER. Requirement for reintervention was an independent risk factor for long-term mortality in a Cox proportional hazard model (hazard ratio, 3.26 [95% CI, 2.53-4.20]). CONCLUSIONS: Reintervention after index TEER is a high-risk procedure that carries a significant mortality burden. This highlights the importance of ensuring procedural success for index TEER to avoid the morbidity of reintervention altogether.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Kaneko T, Newell PC, Nisivaco S, et al. Incidence, characteristics, and outcomes of reintervention after mitral transcatheter edge-to-edge repair. J Thorac Cardiovasc Surg. 2022. PMID: 35570022. doi:10.1016/j.jtcvs.2022.02.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。